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doi:10.1016/j.jmii.2011.01.011Background: In this study, we determined the susceptibility patterns of Staphylococcus aureus
strains to various antimicrobials and prevalence of inducible clindamycin resistance (ICR) in
these isolates.
Methods: Two hundred and one S aureus strains, isolated from various clinical samples, were
included in the study. Antibiotic susceptibilities were studied by disc diffusionmethod on the basis
of theguidelinesby theClinicalandLaboratoryStandards Institute.Thediscdiffusion inductiontest
(D test) was applied to determine ICR resistance among erythromycin-resistant S aureus isolates.
Results: Of the 201 S aureus strains, 101 (50.2%) were resistant to methicillin. All strains were
susceptible to vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid. It was found that
54 (53.4%)methicillin-resistant S aureus (MRSA) strainswereerythromycin resistant, and40 (39.6%)
of themshowedconstitutiveclindamycin resistance. ICRwasdetected in seven(6.9%)MRSAstrains.
Itwasfoundthat13 (13.0%)methicillin-susceptibleSaureus (MSSA) strainswereerythromycin resis-
tant. Constitutive clindamycin resistancewas seen in one (1.0%) MSSA strain, and ICRwas detected
in 10 (10.0%) cases.
Conclusion: There was a high rate of methicillin resistance among S aureus strains in our hospital.
However, no statistically significantdifference of ICRwas observedbetweenMRSAandMSSA strains
(pZ 0.434)orbetween inpatients andoutpatients (pZ 0.804). Itwas concluded that ICR shouldbe
routinely evaluated in each S aureus case to avoid therapy failure among patients.
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58 F. Eksi et al.Introduction Materials and methodsMethicillin resistance in staphylococci is an increasing
problem in clinical practice because methicillin-resistant S
aureus (MRSA) strains are resistant to other antimicrobial
agents and isolates, with reduced susceptibility and resis-
tance to vancomycin have also emerged.1 Once such
a strain is recognized to be the causative agent of an
infection, it is of interest to determine which of the
alternatives to vancomycin is suitable for therapy. In vitro
susceptibilities of MRSA strains, especially those from
community-acquired infections, to clindamycin (CLI),
erythromycin (ERY), quinolone antibiotics, tetracyclines,
and trimethoprim-sulfamethoxazole have frequently been
reported.2,3
The macrolide-lincosamide-streptogramin B (MLSB)
family of antibiotics is commonly used in the treatment of
staphylococcal infections.4 However, this widespread use
has led to an increase in the number of staphylococci
strains resistant to MLSB antibiotics.5,6 Macrolide antibiotic
resistance in S aureus and coagulase-negative staphylococci
may be because of an active efflux mechanism encoded by
msr A (conferring resistance to macrolides and Type B
streptogramins only) or ribosomal target modification
affecting macrolides, lincosamides, and Type B streptog-
ramins (MLSB resistance). erm genes encode enzymes that
confer inducible or constitutive resistance to MLS agents via
methylation of the 23S ribosomal RNA, thereby reducing
binding by MLS agents to the ribosome.4,7 In vitro, S aureus
isolates with constitutive resistance are resistant to ERY
and CLI, and isolates with inducible resistance are resistant
to ERY but appear to be susceptible to CLI. In vivo, therapy
with CLI may select for constitutive erm mutants,8 which
may lead to clinical failure.6,9 Constitutive resistance can
be readily detected, but inducible resistance is not
detectable by routine antimicrobial susceptibility tests.6
According to the recommendation of the Clinical and
Laboratory Standards Institute (CLSI), testing for inducible
clindamycin resistance (ICR) in isolates of staphylococci
should be subjected to the D-zone test.10
In this study, we aimed to determine the susceptibility
pattern of S aureus strains to various antimicrobials. We
also aimed to determine the incidence of MLSB resistance
among S aureus isolates from various clinical samples and
detect ICR strains.Table 1 Distribution of MRSA and MSSA strains according to the
Specimens MRSA
Inpatient isolates Outpatient isolates
Pus 22 d
Blood 22 d
Tracheal aspirate 22 d
Urine 4 4
Throat sample 2 1
Sputum 8 1
Other samples 14 1
Total 94 7
MRSAZmethicillin-resistant Staphylococcus aureus; MSSAZmethicilStaphylococci were recovered from various clinical samples
at the Microbiology Laboratory of Gaziantep University
Hospital from January to November 2007. Duplicate isolates
from the same patient were not included in the study. In
total, 201 S aureus isolates were obtained from clinical
specimens, comprising 147 (73.1%) inpatient and 54 (26.9%)
outpatient isolates. Of the 201 S aureus strains, 52 (25.9%)
were recovered from pus, 38 (18.9%) from blood, 28 (13.9%)
from tracheal aspirates, 21 (10.4%) fromurine, 19 (9.5%) from
throat sample, 18 (9%) from sputum, and 25 (12.4%) from
other samples. Distribution of S aureus strains by origin of
recovery is shown in Table 1.
Definitions of inpatient infections were set according to
the Centers for Disease Control and Prevention,11 which
defines a nosocomial infection as a localized or systemic
condition that results from adverse reaction to the pres-
ence of an infectious agent not present or incubating at the
time of admission to the hospital.
Strains were identified by conventional methods (colony
morphology, Gram stain, catalase activity, slide and tube
coagulase tests, and DNase test) and an automated iden-
tification system (VITEK 2; bioMerieux, St Louis, MO, USA).
For the investigation of methicillin resistance, cefoxitin
discs (30 mg) and oxacillin discs (1 mg) were used. Their
antimicrobial susceptibility tests were performed by disc
diffusion method according to the suggestions of CLSI.10
The isolates were tested for susceptibility to chloram-
phenicol (30 mg), CLI (2 mg), ERY (15 mg), levofloxacin
(5 mg), linezolid (30 mg), quinupristin-dalfopristin (15 mg),
teicoplanin (30 mg), telithromycin (15 mg), trimethoprim-
sulfamethoxazole (1.25/23.75 mg), and vancomycin (30 mg)
(Oxoid, Basingstoke, UK). Quality control was performed
with S aureus strain ATCC 25923; inhibition zone diameters
were in the ranges stipulated by the CLSI.10
Isolates that were CLI susceptible and erythromycin
resistant (ER-R) were tested for inducible resistance by the
D test. A 0.5 McFarland-equivalent suspension of organisms
was inoculated onto a Mueller-Hinton agar plate as
described in the CLSI recommendations.10 CLI and ERY discs
were placed 15e20 mm apart from center to center on
Mueller-Hinton agar plates. Plates were analyzed after 18
hours incubation at 35C. Interpretation of the inhibition
zone diameters was as follows: If an isolate was ER-R andir origin of recovery
MSSA Total, n (%)
Inpatient isolates Outpatient isolates
11 19 52 (25.9)
14 2 38 (18.9)
6 d 28 (13.9)
1 12 21 (10.4)
5 11 19 (9.5)
7 2 18 (9)
9 1 25 (12.4)
53 47 201 (100)
lin-susceptible Staphylococcus aureus.
Antimicrobial resistance of S aureus strains 59CLI susceptible, with a D-shaped inhibition zone around the
CLI disc, it was considered to be positive for inducible
resistance (D test positive). If the isolate was ER-R and CLI
susceptible, with both zones of inhibition showing a circular
shape, the isolate was considered to be negative for
inducible resistance (D test negative), but to have an active
efflux pump. If the isolate was ER-R and CLI resistant, the
isolate was considered to have the macrolide-lincosamide-
streptogramin B constitutive (MLSBC) phenotype.4
Results were analyzed using chi-square test. The statis-
tical analyses were performed using Epi Info version 3.4.3;
Atlanta, GA, USA, and values of p< 0.05 were considered to
indicate statistical significance.
Results
Of the 201 S aureus strains, 101 (50.2%) were resistant to
methicillin (MRSA) and 100 (49.8%) were susceptible to
methicillin (MSSA). The distribution of MSSA strains was as
follows: in 53 of 147 inpatients (36.1%) and in 47 of 54
outpatients (87%). MRSA strains were obtained mostly from
inpatients (nZ 94 of 147; 63.9%).
All isolated S aureus strains were found susceptible to
linezolid, quinupristin/dalfopristin, teicoplanin, and vanco-
mycin. Rates of resistance in MRSA and MSSA to antimicrobial
agents were chloramphenicol, 11% and 5%; CLI, 39.6% and
1%; ERY, 53.4% and 13%; levofloxacin, 52.5% and 1%; teli-
thromycin, 39.6% and 0%; and trimethoprim-sulfamethox-
azole, 10% and 1%, respectively. Antimicrobial susceptibility
results of MRSA and MSSA from inpatients and outpatients are
shown in Table 2. There was a statistically significant
difference of MRSA presence between inpatients (63.9%) and
outpatients (13%) (pZ 0.000). MRSA strains were signifi-
cantly more resistant to ERY (pZ 0.000), telithromycin
(pZ 0.000), levofloxacin (pZ 0.000), and trimethoprim-
sulfamethoxazole (pZ 0.005), when compared with MSSA
strains.
Itwas found that54 (53.4%)MRSAstrainswereERY resistant
and40 (39.6%) of themshowedconstitutiveCLI resistance. ICR
was detected in seven (6.9%) MRSA strains. It was found that
13% of MSSA strains were ERY resistant. Constitutive CLI
resistance was seen in 1% of MSSA strains, and ICR was
detected in10%of thecases (Table3).Therewasa statisticallyTable 2 Antibiotic susceptibility profiles of MRSA and MSSA isol
Antibiotic MRSA (nZ 101)
Inpatient
isolates
(nZ 94)
Outpatient
isolates
(nZ 7)
S I R S I R
Chloramphenicol 84 1 9 5 0 2
Clindamycin 55 0 39 6 0 1
Erythromycin 45 0 49 2 0 5
Levofloxacin 34 11 49 3 0 4
Telithromycin 55 0 39 6 0 1
Trimethoprim-sulfamethoxazole 83 2 9 6 0 1
IZ intermediate; MRSAZmethicillin-resistant Staphylococcus au
RZ resistant; SZ susceptible.significant difference of constitutive CLI resistance in MRSA
strains when compared with MSSA strains (pZ 0.000).
However, no statistically significant difference of ICR was
observed between MRSA and MSSA strains (pZ 0.434) or
between inpatients and outpatients (pZ 0.804).
Discussion
S aureus is one of the important pathogens causing
bacteremia and nosocomial infection. The multidrug resis-
tance to most of the antibiotics used in infections caused by
staphylococci is an increasing problem. The emergence of
methicillin resistance among S aureus strains led to diffi-
culties in the treatment of infections caused by these
microorganisms.12 The very highest rates of methicillin
resistance among S aureus isolates have been noted in
developed countries, and especially in Western Pacific
Regions, both in community-acquired and nosocomial
infections.13
In our study, methicillin resistance of staphylococci was
found to be 50.2%. MRSA prevalence was reported between
33% and 71.3% in several studies from our country.14e16 In
West Asia, MRSA prevalence ranged from 12% to 49.4% in six
different hospitals of Saudi Arabia and was reported to be
62.5% in Pakistan.17,18 In European countries, MRSA rates
varied from 0.6% in Sweden to 40.2%e45% in Belgium,
Greece, Ireland, Italy, the United Kingdom, and Israel.19,20
In the Mediterranean region, the highest overall proportions
of MRSA were reported by Jordan, Egypt, and Cyprus,
where more than 50% of the S aureus blood culture isolates
were methicillin resistant.21 In a study performed in 17
different regions of Russia, methicillin resistance among S
aureus strains was between 0% and 89.5%.22 The differ-
ences in the prevalence of MRSA in different countries
emphasize the importance of local surveillance in gener-
ating relevant local resistance data that can guide empiric
therapy.23
There was a statistically significant difference of MRSA
presence between inpatients (63.9%) and outpatients
(13%) (pZ 0.000). Another study from Pakistan notified
that 62.5% of staphylococci were detected as MRSA and
most of them were recovered from hospitalized patients.18
Shrestha et al.24 reported that 44.9% of MRSA strains wereates
MSSA (nZ 100)
Total
resistance,
n (%)
Inpatient
isolates
(nZ 53)
Outpatient
isolates
(nZ 47)
Total
resistance
rate (%)
S I R S I R
11 (11) 49 1 3 44 1 2 5
40 (39.6) 53 0 0 46 0 1 1
54 (53.4) 46 0 7 41 0 6 13
53 (52.5) 52 0 1 47 0 0 1
40 (39.6) 53 0 0 47 0 0 0
10 (10) 52 1 0 46 0 1 1
reus; MSSAZmethicillin-susceptible Staphylococcus aureus;
Table 3 Susceptibility of Staphylococcus aureus strains to erythromycin and clindamycin
Phenotype MRSA (%) MSSA (%) Total, n (%)
Inpatient
isolates (nZ 94)
Outpatient
isolates (nZ 7)
Total,
n (%)
Inpatient
isolates (nZ 53)
Outpatient
isolates (nZ 47)
Total,
n (%)
ER-S, CL-S 45 2 47 (46.6) 46 41 87 (87) 134 (66.7)
ER-R, CL-R 39 1 40 (39.6) d 1 1 (1) 41 (20.4)
ER-S, CL-R d d d d d d d
ER-R, CL-S, D 4 3 7 (6.9) d 2 2 (2) 9 (4.5)
ER-R, CL-S, Dþ 6 1 7 (6.9) 6 4 10 (10) 17 (8.4)
Total n (%) 101 (50.2) 100 (49.8) 201
CLZ clindamycin; DZ D test negative; DþZ D test positive; ERZ erythromycin; MRSAZmethicillin-resistant Staphylococcus aureus;
MSSAZmethicillin-susceptible Staphylococcus aureus; RZ resistant; SZ susceptible.
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of MRSA was expected in nosocomial infections as the
organisms developed resistance in the closed environ-
ments of hospitals and health care facilities because of
selection pressure and their convenience in spreading from
patient to patient via the health care workers and
instruments.
In our study, despite the high prevalence of MRSA and
increased use of vancomycin and teicoplanin, there was no
isolate with reduced susceptibility to glycopeptides, and all
strains were found susceptible to vancomycin, teicoplanin,
quinupristin/dalfopristin, and linezolid. Although the
isolates in this study were tested in 2007 and no vancomycin
and teicoplanin resistance was found, it should still be
pointed out that disc diffusion test for vancomycin in
staphylococci is no longer recommended by CLSI starting
from 2009 and that the ability of teicoplanin disc diffusion
test to differentiate resistant from susceptible strains is not
known.25
Quinupristin-dalfopristin showed excellent activity,
equal to that of vancomycin, against all S aureus isolates.
Although the bactericidal activity of quinupristin/dalfo-
pristin could be compromised because of the high preva-
lence of ERY-resistant MRSA,26 it might provide a valuable
option for the treatment of MRSA infections. In addition, all
of the isolates were susceptible to the new agent linezolid
although a few isolates of linezolid-resistant S aureus were
reported elsewhere.27,28 Linezolid has limited activity
against selected gram negatives and anaerobes; however, it
is highly active against gram-positive bacteria, including
resistant strains. Like quinupristin/dalfopristin, linezolid is
active against MRSA.27
In this study, it was observed that 10% and 11% of the
MRSA strains were resistant to trimethoprim-sulfamethox-
azole and chloramphenicol, respectively. Most of the MRSA
isolates were resistant to multiple other antimicrobial
agents. In general, elevated rates of multidrug resistance
may emerge from diverse isolates of S aureus under anti-
microbial pressure or as a result of widespread person-to-
person transmission of multidrug resistant isolates.29
In our study, although telithromycin resistance was
detected in 40 (39.6%) MRSA strains, no resistance was
detected in MSSA strains. In this study, telithromycin
was found to be more effective than ERY against MRSA and
MSSA strains. Although resistances to telithromycin and CLI
were similar in MRSA and MSSA strains, telithromycin wasfound to be more effective than CLI because of the induc-
ible resistance in CLI.
The increasing frequency of staphylococcal infections
among patients and changing patterns in antimicrobial
resistance have led to renewed interest in the use of CLI
therapy to treat such infections.30 CLI is indicated for the
treatment of soft tissue infections, pediatric infections
caused by staphylococci, or for patients allergic to beta-
lactam agents.30,31 It is a good alternative to the treatment
of both MRSA and MSSA infections; however, therapeutic
failures caused by inducible MLSB resistance are being
reported more commonly.
In a study from Greece, the constitutive macrolide
resistance phenotype predominated in S aureus strains
(47% MRSA; 13% MSSA) and was followed by the inducible
(15% MRSA; 20% MSSA) and the CLI-susceptible (5%)
phenotypes.32 In Iran, 17 of 175 (9.7%) S aureus isolates
showed ICR; 11 (64.7%) strains were MRSA and 6 (35.3%)
isolates were MSSA.33 In our country, different resistance
rates came from two different studies; in one of them,
the constitutive CLI resistance was 40.9% in MRSA isolates
and 6.3% in MSSA strains, and the inducible resistance
phenotype level was 25.1% in MRSA isolates and 16.4% in
MSSA isolates,34 whereas, in the second one, the consti-
tutive CLI resistance was 43.7% in MRSA isolates and 0% in
MSSA strains, and the inducible resistance phenotype
level was 5.4% in MRSA isolates and 10.7% in MSSA
isolates.35
The incidence of MLSB resistance varies significantly by
geographical region. In Europe, there is a high incidence
(93%) of the constitutive phenotype in MRSA, whereas the
inducible phenotype is predominant in methicillin-suscep-
tible S aureus.36e38 In our study, MRSA strains showed 39.6%
constitutive CLI resistance and 6.9% ICR, whereas MSSA
strains showed 1% constitutive CLI resistance and 10% ICR.
Thus, in MRSA isolates, the level of constitutive CLI resis-
tance was higher than the level of inducible resistance.
Schreckenberger et al.39 reported incidences of ICR to be
between 7% and 12% for MRSA and between 19% and 20% for
MSSA in two different hospitals. Likewise, in our study,
inducible CLI-resistant strains were more prevalent in MSSA
(10%) than in MRSA (6.9%). Nevertheless, this difference
was statistically insignificant (pZ 0.434).
Inducible CLI-resistant staphylococci show susceptible
results in conventional susceptibility tests but can be con-
verted to a constitutively resistant phenotype during CLI
Antimicrobial resistance of S aureus strains 61treatment. As the resistance conversion may result in CLI
treatment failure,40 accurate detection of ICR is necessary
to improve the empirical approaches to the therapy of
serious infections caused by staphylococci.
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